ASIAMEDIC LIMITED

(Incorporated in the Republic of Singapore)
Company Registration No.: 197401556E

(I) THE PROPOSED PLACEMENT OF 51,500,000 NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY; AND
(II) THE PROPOSED IMPLEMENTATION OF THE ASIAMEDIC EMPLOYEE SHARE OPTION SCHEME 2016
- RECEIPT OF LISTING AND QUOTATION NOTICE

*Unless otherwise defined or if the context otherwise requires, capitalised terms used herein shall have the same meaning as ascribed to them in the Company's announcements dated 7 December 2015 and 22 December 2015 (the "**Announcements**") and the Company's circular to Shareholders dated 4 January 2016 (the "**Circular**").*

The Board of Directors of AsiaMedic Limited (the "**Company**") refers to the Announcements and the Circular, and is pleased to announce that the Company has received the listing and quotation notice (the "**LQN**") from the SGX-ST on 7 January 2016 in respect of the listing and quotation of new ordinary shares in the capital of the Company as follows:

(i) 40,000,000 Third Party Placement Shares in respect of the Third Party Placement;

(ii) 11,500,000 Directors Placement Shares in respect of the Proposed Directors Placement; and

(iii) new ESOS Shares pursuant to the exercise of Options granted under the AsiaMedic ESOS.

The LQN in respect of the Third Party Placement Shares, the Directors Placement Shares and the ESOS Shares is subject to the following:

(a) compliance with the SGX-ST's listing requirements; and

(b) Shareholders' approval to be obtained for the Proposed Directors Placement and the Proposed AsiaMedic ESOS at an Extraordinary General Meeting to be convened.

The LQN granted by the SGX-ST is not an indication of the merits of the Third Party Placement and Third Party Placement Shares, the Proposed Directors Placement and Directors Placement Shares, the Proposed AsiaMedic ESOS and ESOS Shares, the Company, its subsidiaries and their securities.

The Company will update Shareholders on the progress of the Third Party Placement, the Proposed Directors Placement and the Proposed AsiaMedic ESOS through further announcement(s) in due course.

BY ORDER OF THE BOARD

Ms Foo Soon Soo
Company Secretary

7 January 2016

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd (the "**Sponsor**"), for compliance with the Listing Manual (Section B: Rules of Catalist) of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**"). The Sponsor has not independently verified the contents of this announcement including the accuracy or completeness of any of the information disclosed or the correctness of any of the statements made, opinions expressed or reports contained in this announcement. This announcement has not been examined or approved by the SGX-ST. The SGX-ST and the Sponsor assume no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made, or reports contained in this announcement.*

The contact person for the Sponsor is Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805, telephone number: (65) 63194954.